Literature DB >> 28449517

The EMPIRICUS trial-the final nail in the coffin of empirical antifungal therapy in the intensive care unit?

Michael Osthoff1, Nina Khanna1, Martin Siegemund.   

Abstract

Year:  2017        PMID： 28449517      PMCID： PMC5393993          DOI： 10.21037/jtd.2017.02.78

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

Review 1.  What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients.

Authors:  Cristóbal León; Luis Ostrosky-Zeichner; Mindy Schuster
Journal:  Intensive Care Med       Date:  2014-04-10       Impact factor: 17.440

2.  Candida as a risk factor for mortality in peritonitis.

Authors:  Philippe Montravers; Hervé Dupont; Remy Gauzit; Benoit Veber; Christian Auboyer; Patrick Blin; Christophe Hennequin; Claude Martin
Journal:  Crit Care Med       Date:  2006-03       Impact factor: 7.598

3.  Nosocomial bloodstream infections in Brazilian hospitals: analysis of 2,563 cases from a prospective nationwide surveillance study.

Authors:  Alexandre R Marra; Luis Fernando Aranha Camargo; Antonio Carlos Campos Pignatari; Teresa Sukiennik; Paulo Renato Petersen Behar; Eduardo Alexandrino Servolo Medeiros; Julival Ribeiro; Evelyne Girão; Luci Correa; Carla Guerra; Carlos Brites; Carlos Alberto Pires Pereira; Irna Carneiro; Marise Reis; Marta Antunes de Souza; Regina Tranchesi; Cristina U Barata; Michael B Edmond
Journal:  J Clin Microbiol       Date:  2011-03-16       Impact factor: 5.948

4.  Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia.

Authors:  David Andes; Paul G Ambrose; Jeffrey P Hammel; Scott A Van Wart; Varsha Iyer; Daniel K Reynolds; Donald N Buell; Laura L Kovanda; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2011-02-07       Impact factor: 5.191

5.  MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.

Authors:  Luis Ostrosky-Zeichner; Shmuel Shoham; Jose Vazquez; Annette Reboli; Robert Betts; Michelle A Barron; Mindy Schuster; Marc A Judson; Sanjay G Revankar; Juan Pablo Caeiro; Julie E Mangino; David Mushatt; Roger Bedimo; Alison Freifeld; Minh Hong Nguyen; Carol A Kauffman; William E Dismukes; Andrew O Westfall; Jeanna Beth Deerman; Craig Wood; Jack D Sobel; Peter G Pappas
Journal:  Clin Infect Dis       Date:  2014-02-18       Impact factor: 9.079

6.  International study of the prevalence and outcomes of infection in intensive care units.

Authors:  Jean-Louis Vincent; Jordi Rello; John Marshall; Eliezer Silva; Antonio Anzueto; Claude D Martin; Rui Moreno; Jeffrey Lipman; Charles Gomersall; Yasser Sakr; Konrad Reinhart
Journal:  JAMA       Date:  2009-12-02       Impact factor: 56.272

7.  Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial.

Authors:  Mindy G Schuster; John E Edwards; Jack D Sobel; Rabih O Darouiche; Adolf W Karchmer; Susan Hadley; Gus Slotman; Helene Panzer; Pinaki Biswas; John H Rex
Journal:  Ann Intern Med       Date:  2008-07-15       Impact factor: 25.391

8.  Diagnostic performance of the (1-->3)-beta-D-glucan assay for invasive fungal disease.

Authors:  Sophia Koo; Julie M Bryar; John H Page; Lindsey R Baden; Francisco M Marty
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

9.  β-glucan antigenemia anticipates diagnosis of blood culture-negative intraabdominal candidiasis.

Authors:  Frederic Tissot; Frederic Lamoth; Philippe M Hauser; Christina Orasch; Ursula Flückiger; Martin Siegemund; Stefan Zimmerli; Thierry Calandra; Jacques Bille; Philippe Eggimann; Oscar Marchetti
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

10.  Diagnosis of invasive candidiasis in the ICU.

Authors:  Philippe Eggimann; Jacques Bille; Oscar Marchetti
Journal:  Ann Intensive Care       Date:  2011-09-01       Impact factor: 6.925
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.